Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech, Chromsystems Partner on Mass Spec for Clinical Research

NEW YORK (GenomeWeb News) – Life Technologies said today that its Applied Biosystems group has partnered with Chromsystems Instruments & Chemicals to offer integrated workflows for mass spectrometry applications in the clinical research market.

Under the agreement, the companies have combined Chromsystems’ reagent kits, calibrators, and controls with AB Sciex mass spectrometers and software for use in clinical research environments.

The company said that the combined solutions could “accelerate the adoption of new tests, including vitamin D, amino acids, acylcarnitines, immunosuppressants, antidepressants and neuroleptics, for medically-relevant research. “

ABI said that it has expanded its iMethod line of pre-configured lab workflows in order to optimize Chromsystems’ chemistries on AB Sciex triple quadrupole and QTRAP LC/MS/MS systems. Improvements include an "enhanced" version of its ChemoView software to simplify data interpretation.

The systems, software and test methods were developed as part of a joint venture between ABI and MDS Analytical Technologies.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.